Sunday, September 14, 2014 Last update: 8:33 PM
FreshNews.com - All Company Technology News Since 1996

Exact Sciences to host second-quarter 2014 results, annual meeting webcasts and calls

Companies mentioned in this article: EXACT Sciences Corp.

MADISON, Wis. -- (BUSINESS WIRE) -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will host webcasts and conference calls to discuss its second-quarter 2014 financial results and of its annual meeting of stockholders.

Second-Quarter 2014 Webcast & Conference Call Details

 
Date:     Tuesday, July 22, 2014
Time: 10 a.m. ET, 9 a.m. CT
Webcast:

The live webcast can be accessed at www.exactsciences.com

Telephone: Domestic callers, dial 877-212-6082
International callers, dial 707-287-9332
Access code for both domestic and international callers: 74628686
 

Annual Meeting of Stockholders Webcast & Conference Call Details

 
Date: Thursday, July 24, 2014
Time: 11 a.m. ET, 10 a.m. CT
Webcast:

The live webcast can be accessed at www.exactsciences.com

Telephone: Domestic callers, dial 877-212-6082
International callers, dial 707-287-9332

Access code for both domestic and international callers: 75588231

An archive of the webcast will be available at www.exactsciences.com. A replay of the second-quarter and annual meeting conference calls will be available by calling 855-859-2056 domestically or 404-537-3406 internationally. The access code for the replay of the second-quarter call is 74628686. The annual meeting replay can be accessed with the code 75588231. The webcasts, conference calls and replays are open to all interested parties.

About Exact Sciences Corp.

Exact Sciences Corp. is a molecular diagnostics company focused on colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer. For more information, please visit the company’s website at www.exactsciences.com.

Certain statements made in this news release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “could,” “seek,” “intend,” “plan,” “estimate,” “anticipate” or other comparable terms. Forward-looking statements in this news release may address the following subjects among others: statements regarding the sufficiency of our capital resources, expectations concerning our ability to secure and the timing of FDA approval of and reimbursement for our Cologuard test, our estimated reimbursement amounts, our estimates of the available market size and our potential penetration, expected research and development expenses, expected general and administrative expenses and our expectations concerning our business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.


Copyright © Business Wire 2014
Contact:

The Luminis Group Ltd. for Exact Sciences Corp.
Rod Hise
608-807-4607
rod@rodhise.com